Hims GLP-1 Weight Loss Review 2026: Worth It? Cost, Pros & Cons

Quick answer: Is Hims GLP-1 worth it in 2026?

Hims & Hers offers brand-name Wegovy through their Novo Nordisk partnership, making them one of the most recognized names in telehealth GLP-1 prescribing. At approximately $448 per month (including membership and medication), Hims is one of the more expensive options — costing more than Ro Body ($373+) and significantly more than compounded providers like Found ($99) or Eden ($99). Hims' strengths are brand recognition, a simple user experience, and Wegovy pill access.

What is Hims & Hers GLP-1?

Hims & Hers is one of the largest publicly traded telehealth companies in the US. Their GLP-1 weight loss program offers brand-name FDA-approved Wegovy (semaglutide) through a partnership with Novo Nordisk. After transitioning away from compounded semaglutide, Hims now focuses exclusively on brand-name medication — both the Wegovy injection and the new Wegovy oral pill launched in January 2026.

Hims GLP-1 pricing breakdown

Last verified: August 2026. The biggest pricing trap with Hims is the $188 first-month teaser rate that reverts to $448/month ongoing. Always calculate based on the ongoing rate, not the intro price.

The 12-month true cost of Hims GLP-1 is approximately $5,076 (factoring in the first-month discount). This is one of the highest among telehealth providers — more expensive than Ro Body ($4,476) and far more than compounded options.

Hims GLP-1 pros and cons

Pros

• Brand-name Wegovy only: FDA-approved medication, not compounded
• Wegovy pill access: Offers the new oral Wegovy tablet
• Strong brand recognition: One of the most trusted telehealth brands
• Simple, streamlined process: Clean app and straightforward intake
• Insurance verification: Can check coverage and help with prior authorization
• Licensed in all 50 states

Cons

• Most expensive major provider: At $448/month, costs more than Ro ($373) and all compounded options
• Teaser pricing trap: $188 first month reverts to $448 — the biggest verified gap in the industry
• No compounded option: If you want cheaper compounded GLP-1s, Hims doesn't offer them
• No tirzepatide: Only offers Wegovy (semaglutide), not Zepbound or Mounjaro
• Membership required: $149/month membership on top of medication cost

Hims vs Ro: Which is better?

Hims and Ro Body are the two biggest names in brand-name GLP-1 telehealth. Here's how they compare:

Ro Body wins on price and insurance support. Hims wins on brand simplicity. Both offer the same medication. For a full comparison including compounded providers, see our best GLP-1 telehealth guide.

Who is Hims GLP-1 best for?

• People who want brand-name FDA-approved Wegovy from a well-known company
• People who value a simple, streamlined digital experience
• People who may have insurance coverage for Wegovy
• People who want the Wegovy pill format

Hims is not ideal for budget-conscious patients (choose Found or Eden), those who want tirzepatide, or those who want compounded options (choose Henry Meds).

The bottom line

Hims & Hers is a reputable, well-known telehealth provider offering brand-name Wegovy. However, at $448/month, it's the most expensive major GLP-1 telehealth option. The teaser pricing trap ($188 first month → $448 ongoing) is the biggest in the industry. If you want brand-name Wegovy,Ro Body offers a similar experience at a lower price. If cost is your priority, explore cheaper GLP-1 options.

Frequently asked questions

Is the Hims $188/month price real?

The $188 is a first-month promotional rate only. After the first month, the price reverts to approximately $448/month. This is the largest verified teaser-to-ongoing price gap in the GLP-1 telehealth market.

Does Hims offer tirzepatide (Zepbound)?

No. Hims currently only offers Wegovy (semaglutide). If you want tirzepatide, see our tirzepatide buying guide.

Can I use my HSA/FSA for Hims GLP-1?

Yes, HSA and FSA funds can typically be used for GLP-1 weight loss programs if you have a prescription. Check with your HSA/FSA administrator for eligibility.